Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2024

Open Access 01-12-2024 | Biomarkers | Review

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

Authors: Kai He, Maryam Baniasad, Hyunwoo Kwon, Tomislav Caval, Gege Xu, Carlito Lebrilla, Daniel W. Hommes, Carolyn Bertozzi

Published in: Journal of Hematology & Oncology | Issue 1/2024

Login to get access

Abstract

Cancer early detection and treatment response prediction continue to pose significant challenges. Cancer liquid biopsies focusing on detecting circulating tumor cells (CTCs) and DNA (ctDNA) have shown enormous potential due to their non-invasive nature and the implications in precision cancer management. Recently, liquid biopsy has been further expanded to profile glycoproteins, which are the products of post-translational modifications of proteins and play key roles in both normal and pathological processes, including cancers. The advancements in chemical and mass spectrometry-based technologies and artificial intelligence-based platforms have enabled extensive studies of cancer and organ-specific changes in glycans and glycoproteins through glycomics and glycoproteomics. Glycoproteomic analysis has emerged as a promising tool for biomarker discovery and development in early detection of cancers and prediction of treatment efficacy including response to immunotherapies. These biomarkers could play a crucial role in aiding in early intervention and personalized therapy decisions. In this review, we summarize the significant advance in cancer glycoproteomic biomarker studies and the promise and challenges in integration into clinical practice to improve cancer patient care.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
2.
Raufaste-Cazavieille V, Santiago R, Droit A. Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology. Front Mol Biosci. 2022;9:962743.PubMedPubMedCentralCrossRef
3.
Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971–83.PubMedCrossRef
4.
Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452:571–9.PubMedCrossRef
5.
Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, Pellè E, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol. 2018;10:1758835918794630.PubMedPubMedCentralCrossRef
6.
Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11:858–73.PubMedCrossRef
7.
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312.PubMedCrossRef
8.
9.
Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–30.PubMedPubMedCentralCrossRef
10.
Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006;126:855–67.PubMedCrossRef
11.
Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020;21:729–49.PubMedCrossRef
12.
Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5:526–42.PubMedCrossRef
13.
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.PubMedCrossRef
14.
Carvalho S, Catarino TA, Dias AM, Kato M, Almeida A, Hessling B, et al. Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer. Oncogene. 2016;35:1619–31.PubMedCrossRef
15.
Taniguchi N, Kizuka Y. Glycans and Cancer. 2015. p. 11–51.
16.
Rodrigues JG, Balmaña M, Macedo JA, Poças J, Fernandes Â, de-Freitas-Junior JCM, et al. Glycosylation in cancer: selected roles in tumour progression, immune modulation and metastasis. Cell Immunol. 2018;333:46–57.PubMedCrossRef
17.
Ignatiadis M, Lee M, Jeffrey SS. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res. 2015;21:4786–800.PubMedCrossRef
18.
Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022;132:1–10.CrossRef
19.
Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer. 2014;14:623–31.PubMedCrossRef
20.
Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5:145.PubMedPubMedCentralCrossRef
21.
Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 2018;36:1631–41.PubMedCrossRef
22.
Cree IA, Deans Z, Ligtenberg MJL, Normanno N, Edsjö A, Rouleau E, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67:923–31.PubMedCrossRef
23.
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–38.PubMedCrossRef
24.
Zhou J, Kulasinghe A, Bogseth A, O’Byrne K, Punyadeera C, Papautsky I. Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. Microsyst Nanoeng. 2019;5:8.PubMedPubMedCentralCrossRef
25.
26.
Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015;12:685–91.PubMedPubMedCentralCrossRef
27.
Bronkhorst AJ, Ungerer V, Holdenrieder S. Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations. Crit Rev Clin Lab Sci. 2019;57:253–69.PubMedCrossRef
28.
29.
30.
Walsh G. Post-translational modifications of protein biopharmaceuticals. Drug Discov Today. 2010;15:773–80.PubMedCrossRef
31.
Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem. 2010;56:223–36.PubMedCrossRef
32.
Trbojević-Akmačić I, Lageveen-Kammeijer GSM, Heijs B, Petrović T, Deriš H, Wuhrer M, et al. High-throughput glycomic methods. Chem Rev. 2022;122:15865–913.PubMedPubMedCentralCrossRef
33.
Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. Curr Opin Struct Biol. 2011;21:576–82.PubMedCrossRef
34.
Schiel JE. Glycoprotein analysis using mass spectrometry: unraveling the layers of complexity. Anal Bioanal Chem. 2012;404:1141–9.PubMedCrossRef
35.
Ruhaak LR, Xu G, Li Q, Goonatilleke E, Lebrilla CB. Mass spectrometry approaches to glycomic and glycoproteomic analyses. Chem Rev. 2018;118:7886–930.PubMedPubMedCentralCrossRef
36.
Levery SB, Steentoft C, Halim A, Narimatsu Y, Clausen H, Vakhrushev SY. Advances in mass spectrometry driven O-glycoproteomics. Biochim Biophys Acta. 2015;1850:33–42.PubMedCrossRef
37.
Banazadeh A, Veillon L, Wooding KM, Zabet-Moghaddam M, Mechref Y. Recent advances in mass spectrometric analysis of glycoproteins. Electrophoresis. 2017;38:162–89.PubMedCrossRef
38.
Tamara S, Franc V, Heck AJR. A wealth of genotype-specific proteoforms fine-tunes hemoglobin scavenging by haptoglobin. Proc Natl Acad Sci U S A. 2020;117:15554–64.PubMedPubMedCentralCrossRef
39.
Oh MJ, Lee SH, Kim U, An HJ. In-depth investigation of altered glycosylation in human haptoglobin associated cancer by mass spectrometry. Mass Spectrom Rev. 2023;42:496–518.PubMedCrossRef
40.
Fujimura T, Shinohara Y, Tissot B, Pang P-C, Kurogochi M, Saito S, et al. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer. 2008;122:39–49.PubMedCrossRef
41.
Turner GA. Haptoglobin: a potential reporter molecule for glycosylation changes in disease. Adv Exp Med Biol. 1995;1995(376):231–8.CrossRef
42.
43.
Noda K, Miyoshi E, Uozumi N, Yanagidani S, Ikeda Y, Gao C, et al. Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. Hepatology. 1998;28:944–52.PubMedCrossRef
44.
Liu Y-C, Yen H-Y, Chen C-Y, Chen C-H, Cheng P-F, Juan Y-H, et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci U S A. 2011;108:11332–7.PubMedPubMedCentralCrossRef
45.
Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, et al. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol. 2010;4:98–118.PubMedCrossRef
46.
Hiraiwa N, Yabuta T, Yoritomi K, Hiraiwa M, Tanaka Y, Suzuki T, et al. Transactivation of the fucosyltransferase VII gene by human T-cell leukemia virus type 1 Tax through a variant cAMP-responsive element. Blood. 2003;101:3615–21.PubMedCrossRef
47.
Matsuura N, Narita T, Hiraiwa N, Hiraiwa M, Murai H, Iwase T, et al. Gene expression of fucosyl- and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in human breast cancer. Int J Oncol. 1998;12:1157–64.PubMed
48.
Holmes EH, Hakomori S, Ostrander GK. Synthesis of type 1 and 2 lacto series glycolipid antigens in human colonic adenocarcinoma and derived cell lines is due to activation of a normally unexpressed beta 1–3N-acetylglucosaminyltransferase. J Biol Chem. 1987;262:15649–58.PubMedCrossRef
49.
Guo H, Nagy T, Pierce M. Post-translational glycoprotein modifications regulate colon cancer stem cells and colon adenoma progression in Apc(min/+) mice through altered Wnt receptor signaling. J Biol Chem. 2014;289:31534–49.PubMedPubMedCentralCrossRef
50.
Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Taniguchi N. Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci U S A. 1995;92:8754–8.PubMedPubMedCentralCrossRef
51.
Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, et al. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol. 2019;15:e8793.PubMedPubMedCentralCrossRef
52.
Wang G, Li J, Bojmar L, Chen H, Li Z, Tobias GC, et al. Tumour extracellular vesicles and particles induce liver metabolic dysfunction. Nature. 2023;618:374–82.PubMedPubMedCentralCrossRef
53.
Jiao Y, Xu P, Shi H, Chen D, Shi H. Advances on liver cell-derived exosomes in liver diseases. J Cell Mol Med. 2021;25:15–26.PubMedCrossRef
54.
Zhu J, Wu J, Yin H, Marrero J, Lubman DM. Mass spectrometric N-glycan analysis of haptoglobin from patient serum samples using a 96-well plate format. J Proteome Res. 2015;14:4932–9.PubMedPubMedCentralCrossRef
55.
56.
Zhu J, Warner E, Parikh ND, Lubman DM. Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches. Mass Spectrom Rev. 2019;38:265–90.PubMedCrossRef
57.
Čaval T, Lin Y-H, Varkila M, Reiding KR, Bonten MJM, Cremer OL, et al. Glycoproteoform profiles of individual patients’ plasma alpha-1-antichymotrypsin are unique and extensively remodeled following a septic episode. Front Immunol. 2020;11:608466.PubMedCrossRef
58.
Keser T, Tijardović M, Gornik I, Lukić E, Lauc G, Gornik O, et al. High-throughput and site-specific N-glycosylation analysis of human alpha-1-acid glycoprotein offers a great potential for new biomarker discovery. Mol Cell Proteomics. 2021;20:100044.PubMedPubMedCentralCrossRef
59.
Virág D, Kremmer T, Lőrincz K, Kiss N, Jobbágy A, Bozsányi S, et al. Altered glycosylation of human alpha-1-acid glycoprotein as a biomarker for malignant melanoma. Molecules. 2021;26:6003.PubMedPubMedCentralCrossRef
60.
Yokobori T, Yazawa S, Asao T, Nakazawa N, Mogi A, Sano R, et al. Fucosylated α1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer. Sci Rep. 2019;9:14503.PubMedPubMedCentralCrossRef
61.
Yazawa S, Takahashi R, Yokobori T, Sano R, Mogi A, Saniabadi AR, et al. Fucosylated glycans in α1-acid glycoprotein for monitoring treatment outcomes and prognosis of cancer patients. PLoS ONE. 2016;11:e0156277.PubMedPubMedCentralCrossRef
62.
63.
de Vroome SW, Holst S, Girondo MR, van der Burgt YEM, Mesker WE, Tollenaar RAEM, et al. Serum N-glycome alterations in colorectal cancer associate with survival. Oncotarget. 2018;9:30610–23.PubMedPubMedCentralCrossRef
64.
Dotz V, Wuhrer M. N-glycome signatures in human plasma: associations with physiology and major diseases. FEBS Lett. 2019;593:2966–76.PubMedCrossRef
65.
Pickering C, Aiyetan P, Xu G, Mitchell A, Rice R, Najjar YG, et al. Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy. Front Immunol. 2023;14:1187332.PubMedPubMedCentralCrossRef
66.
Desai K, Gupta S, May FP, Xu G, Shaukat A, Hommes DW, et al. Early detection of advanced adenomas and colorectal carcinoma by serum glycoproteome profiling. Gastroenterology. 2024;166:194-197.e2.PubMedCrossRef
67.
Chen M, Ren AH, Prassas I, Soosaipillai A, Lim B, Fraser DD, et al. Plasma protein profiling by proximity extension assay technology reveals novel biomarkers of traumatic brain injury—a pilot study. J Appl Lab Med. 2021;6:1165–78.PubMedCrossRef
68.
Wik L, Nordberg N, Broberg J, Björkesten J, Assarsson E, Henriksson S, et al. Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Mol Cell Proteomics. 2021;20:100168.PubMedPubMedCentralCrossRef
69.
Pietzner M, Wheeler E, Carrasco-Zanini J, Kerrison ND, Oerton E, Koprulu M, et al. Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. Nat Commun. 2021;12:6822.PubMedPubMedCentralCrossRef
70.
Dwek MV, Jenks A, Leathem AJC. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin Chim Acta. 2010;411:1935–9.PubMedCrossRef
71.
Bojar D, Meche L, Meng G, Eng W, Smith DF, Cummings RD, et al. A useful guide to lectin binding: machine-learning directed annotation of 57 unique lectin specificities. ACS Chem Biol. 2022;17:2993–3012.PubMedPubMedCentralCrossRef
72.
De Leoz MLA, Duewer DL, Fung A, Liu L, Yau HK, Potter O, et al. NIST interlaboratory study on glycosylation analysis of monoclonal antibodies: comparison of results from diverse analytical methods. Mol Cell Proteomics. 2020;19:11–30.PubMedCrossRef
73.
74.
Kailemia MJ, Park D, Lebrilla CB. Glycans and glycoproteins as specific biomarkers for cancer. Anal Bioanal Chem. 2017;409:395–410.PubMedCrossRef
75.
Melmer M, Stangler T, Premstaller A, Lindner W. Comparison of hydrophilic-interaction, reversed-phase and porous graphitic carbon chromatography for glycan analysis. J Chromatogr A. 2011;1218:118–23.PubMedCrossRef
76.
Ruhaak LR, Deelder AM, Wuhrer M. Oligosaccharide analysis by graphitized carbon liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2009;394:163–74.PubMedCrossRef
77.
Zhang C, Ye Z, Xue P, Shu Q, Zhou Y, Ji Y, et al. Evaluation of different N-glycopeptide enrichment methods for N-glycosylation sites mapping in mouse brain. J Proteome Res. 2016;15:2960–8.PubMedCrossRef
78.
Liu Z, Xu M, Zhang W, Miao X, Wang PG, Li S, et al. Recent development in hydrophilic interaction liquid chromatography stationary materials for glycopeptide analysis. Anal Methods. 2022;14:4437–48.PubMedCrossRef
79.
Balaguer E, Neusüss C. Glycoprotein characterization combining intact protein and glycan analysis by capillary electrophoresis-electrospray ionization-mass spectrometry. Anal Chem. 2006;78:5384–93.PubMedCrossRef
80.
Lingg N, Zhang P, Song Z, Bardor M. The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis. Biotechnol J. 2012;7:1462–72.PubMedCrossRef
81.
82.
Song E, Pyreddy S, Mechref Y. Quantification of glycopeptides by multiple reaction monitoring liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2012;26:1941–54.PubMedPubMedCentralCrossRef
83.
84.
Varki A, Cummings R, Esko JD. Essentials of Glycobiology. 2022.
85.
Wohlgemuth J, Karas M, Eichhorn T, Hendriks R, Andrecht S. Quantitative site-specific analysis of protein glycosylation by LC-MS using different glycopeptide-enrichment strategies. Anal Biochem. 2009;395:178–88.PubMedCrossRef
86.
Goumenou A, Delaunay N, Pichon V. Recent advances in lectin-based affinity sorbents for protein glycosylation studies. Front Mol Biosci. 2021;8:746822.PubMedPubMedCentralCrossRef
87.
Hong Q, Ruhaak LR, Stroble C, Parker E, Huang J, Maverakis E, et al. A method for comprehensive glycosite-mapping and direct quantitation of serum glycoproteins. J Proteome Res. 2015;14:5179–92.PubMedPubMedCentralCrossRef
88.
Ongay S, Boichenko A, Govorukhina N, Bischoff R. Glycopeptide enrichment and separation for protein glycosylation analysis. J Sep Sci. 2012;35:2341–72.PubMedCrossRef
89.
Xue Y, Xie J, Fang P, Yao J, Yan G, Shen H, et al. Study on behaviors and performances of universal N-glycopeptide enrichment methods. Analyst. 2018;143:1870–80.PubMedCrossRef
90.
Huang Y, Nie Y, Boyes B, Orlando R. Resolving isomeric glycopeptide glycoforms with hydrophilic interaction chromatography (HILIC). J Biomol Tech. 2016;27:98–104.PubMedPubMedCentralCrossRef
91.
Mookherjee A, Guttman M. Bridging the structural gap of glycoproteomics with ion mobility spectrometry. Curr Opin Chem Biol. 2018;42:86–92.PubMedCrossRef
92.
Makrydaki E, Kotidis P, Polizzi KM, Kontoravdi C. Hitting the sweet spot with capillary electrophoresis: advances in N-glycomics and glycoproteomics. Curr Opin Biotechnol. 2021;71:182–90.PubMedCrossRef
93.
Macklin A, Khan S, Kislinger T. Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clin Proteomics. 2020;17:17.PubMedPubMedCentralCrossRef
94.
95.
Miyamoto S, Stroble CD, Taylor S, Hong Q, Lebrilla CB, Leiserowitz GS, et al. Multiple reaction monitoring for the quantitation of serum protein glycosylation profiles: application to ovarian cancer. J Proteome Res. 2018;17:222–33.PubMedCrossRef
96.
Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4:256–69.PubMed
97.
Kirwan A, Utratna M, O’Dwyer ME, Joshi L, Kilcoyne M. Glycosylation-based serum biomarkers for cancer diagnostics and prognostics. Biomed Res Int. 2015;2015:1–16.CrossRef
98.
Li F, Li C, Wang M, Webb GI, Zhang Y, Whisstock JC, et al. GlycoMine: a machine learning-based approach for predicting N-, C- and O-linked glycosylation in the human proteome. Bioinformatics. 2015;31:1411–9.PubMedCrossRef
99.
Sato T, Furukawa K, Greenwalt DE, Kobata A. Most bovine milk fat globule membrane glycoproteins contain asparagine-linked sugar chains with GalNAc beta 1–>4GlcNAc groups. J Biochem. 1993;114:890–900.PubMedCrossRef
100.
FDA Center for Devices and Radiological Health. AFP-L3% Immunological Test Systems - Class II Special Controls Guidance Document for Industry and FDA Staff. 2005 Oct.
101.
Kim H, Kim K, Jin J, Park J, Yu SJ, Yoon J-H, et al. Measurement of glycosylated alpha-fetoprotein improves diagnostic power over the native form in hepatocellular carcinoma. PLoS ONE. 2014;9:e110366.PubMedPubMedCentralCrossRef
102.
Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313:15–9.PubMedCrossRef
103.
Choi J, Kim G, Han S, Lee W, Chun S, Lim Y. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology. 2019;69:1983–94.PubMedCrossRef
104.
Dunbar C, Kushnir MM, Yang YK. Glycosylation profiling of the neoplastic biomarker alpha fetoprotein through intact mass protein analysis. J Proteome Res. 2023;22:226–34.PubMedCrossRef
105.
106.
Valmu L, Alfthan H, Hotakainen K, Birken S, Stenman U-H. Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography–electrospray mass spectrometry. Glycobiology. 2006;16:1207–18.PubMedCrossRef
107.
Elliott MM, Kardana A, Lustbader JW, Cole LA. Carbohydrate and peptide structure of the alpha- and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine. 1997;7:15–32.PubMedCrossRef
108.
Terävä J, Tiainen L, Lamminmäki U, Kellokumpu-Lehtinen P-L, Pettersson K, Gidwani K. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15–3 (CA15-3) in human plasma. PLoS ONE. 2019;14:e0219480.PubMedPubMedCentralCrossRef
109.
Choi JW, Moon B-I, Lee JW, Kim HJ, Jin Y, Kim H-J. Use of CA15-3 for screening breast cancer: an antibody-lectin sandwich assay for detecting glycosylation of CA15-3 in sera. Oncol Rep. 2018;40:145–54.PubMedPubMedCentral
110.
Chen W, Zhang Z, Zhang S, Zhu P, Ko JK-S, Yung KK-L. MUC1: structure, function, and clinic application in epithelial cancers. Int J Mol Sci. 2021;22:6567.PubMedPubMedCentralCrossRef
111.
Scarà S, Bottoni P, Scatena R. CA 19–9: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:247–60.PubMedCrossRef
112.
113.
Duffy MJ. CA 19–9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem. 1998;35(Pt 3):364–70.PubMedCrossRef
114.
Bayoumy S, Hyytiä H, Leivo J, Talha SM, Huhtinen K, Poutanen M, et al. Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125. Commun Biol. 2020;3:460.PubMedPubMedCentralCrossRef
115.
Chen K, Gentry-Maharaj A, Burnell M, Steentoft C, Marcos-Silva L, Mandel U, et al. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J Proteome Res. 2013;12:1408–18.PubMedCrossRef
116.
Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, et al. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int J Gynecol Cancer. 2012;22:531–8.PubMedCrossRef
117.
Zhao Q, Zhan T, Deng Z, Li Q, Liu Y, Yang S, et al. Glycan analysis of colorectal cancer samples reveals stage-dependent changes in CEA glycosylation patterns. Clin Proteomics. 2018;15:9.PubMedPubMedCentralCrossRef
118.
Pont L, Kuzyk V, Benavente F, Sanz-Nebot V, Mayboroda OA, Wuhrer M, et al. Site-specific N-linked glycosylation analysis of human carcinoembryonic antigen by sheathless capillary electrophoresis-tandem mass spectrometry. J Proteome Res. 2021;20:1666–75.PubMedPubMedCentralCrossRef
119.
Gebauer F, Wicklein D, Horst J, Sundermann P, Maar H, Streichert T, et al. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. PLoS ONE. 2014;9:e113023.PubMedPubMedCentralCrossRef
120.
Zhang X, Han X, Zuo P, Zhang X, Xu H. CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration. J Int Med Res. 2020;48:300060520959478.PubMed
121.
Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32:643–71.PubMedCrossRef
122.
Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test. JAMA. 2014;311:1143.PubMedCrossRef
123.
Thompson IM. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA. 2005;294:66.PubMedCrossRef
124.
Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O’Kennedy RJ. Aberrant PSA glycosylation—a sweet predictor of prostate cancer. Nat Rev Urol. 2013;10:99–107.PubMedCrossRef
125.
Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res. 2009;8:613–9.PubMedPubMedCentralCrossRef
126.
Peracaula R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology. 2003;13:457–70.PubMedCrossRef
127.
128.
Wang C, Höti N, Lih T-SM, Sokoll LJ, Zhang R, Zhang Z, et al. Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA. Clin Proteomics. 2019;16:1–18.PubMedPubMedCentralCrossRef
129.
Ferrer-Batallé M, Llop E, Ramírez M, Aleixandre R, Saez M, Comet J, et al. Comparative study of blood-based biomarkers, α2,3-sialic acid PSA and PHI, for high-risk prostate cancer detection. Int J Mol Sci. 2017;18:845.PubMedPubMedCentralCrossRef
130.
Ishikawa T, Yoneyama T, Tobisawa Y, Hatakeyama S, Kurosawa T, Nakamura K, et al. An automated micro-total immunoassay system for measuring cancer-associated α2,3-linked sialyl N-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis. Int J Mol Sci. 2017;18:470.PubMedPubMedCentralCrossRef
131.
Yoneyama T, Ohyama C, Hatakeyama S, Narita S, Habuchi T, Koie T, et al. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem Biophys Res Commun. 2014;448:390–6.PubMedCrossRef
132.
Kaya T, Kaneko T, Kojima S, Nakamura Y, Ide Y, Ishida K, et al. High-sensitivity immunoassay with surface plasmon field-enhanced fluorescence spectroscopy using a plastic sensor chip: application to quantitative analysis of total prostate-specific antigen and GalNAcβ1–4GlcNAc-linked prostate-specific antigen for prostate cancer diagnosis. Anal Chem. 2015;87:1797–803.PubMedCrossRef
133.
Llop E, Ferrer-Batallé M, Barrabés S, Guerrero PE, Ramírez M, Saldova R, et al. Improvement of prostate cancer diagnosis by detecting PSA glycosylation-specific changes. Theranostics. 2016;6:1190–204.PubMedPubMedCentralCrossRef
134.
Fujita K, Hatano K, Tomiyama E, Hayashi Y, Matsushita M, Tsuchiya M, et al. Serum core-type fucosylated prostate-specific antigen index for the detection of high-risk prostate cancer. Int J Cancer. 2021;148:3111–8.PubMedCrossRef
135.
Yoneyama T, Tobisawa Y, Kaneko T, Kaya T, Hatakeyama S, Mori K, et al. Clinical significance of the Lacdi <scp>NA</scp> c-glycosylated prostate-specific antigen assay for prostate cancer detection. Cancer Sci. 2019;110:2573–89.PubMedPubMedCentralCrossRef
136.
Leymarie N, Griffin PJ, Jonscher K, Kolarich D, Orlando R, McComb M, et al. Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics. 2013;12:2935–51.PubMedPubMedCentralCrossRef
137.
Saeland E, Belo AI, Mongera S, van Die I, Meijer GA, van Kooyk Y. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int J Cancer. 2012;131:117–28.PubMedCrossRef
138.
van Gisbergen KPJM, Aarnoudse CA, Meijer GA, Geijtenbeek TBH, van Kooyk Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3–grabbing nonintegrin. Cancer Res. 2005;65:5935–44.PubMedCrossRef
139.
140.
Rangel-Angarita V, Malaker SA. Mucinomics as the Next Frontier of Mass Spectrometry. ACS Chem Biol. 2021;16:1866–83.PubMedCrossRef
141.
142.
Malaker SA, Pedram K, Ferracane MJ, Bensing BA, Krishnan V, Pett C, et al. The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proc Natl Acad Sci. 2019;116:7278–87.PubMedPubMedCentralCrossRef
143.
Kletter D, Cao Z, Bern M, Haab B. Determining lectin specificity from glycan array data using motif segregation and glycosearch software. Curr Protoc Chem Biol. 2013;5:157–69.PubMedPubMedCentralCrossRef
144.
Kim H, Park S, Jeong IG, Song SH, Jeong Y, Kim C-S, et al. Noninvasive precision screening of prostate cancer by urinary multimarker sensor and artificial intelligence analysis. ACS Nano. 2021;15:4054–65.PubMedCrossRef
145.
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28:2159–66.PubMedPubMedCentralCrossRef
146.
Füzéry AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. 2013;10:13.PubMedPubMedCentralCrossRef
147.
148.
149.
Yin H, Zhu J. Methods for quantification of glycopeptides by liquid separation and mass spectrometry. Mass Spectrom Rev. 2023;42:887–917.PubMedCrossRef
150.
Hong Q, Lebrilla CB, Miyamoto S, Ruhaak LR. Absolute quantitation of immunoglobulin g and its glycoforms using multiple reaction monitoring. Anal Chem. 2013;85:8585–93.PubMedCrossRef
151.
Krishnan S, Shimoda M, Sacchi R, Kailemia MJ, Luxardi G, Kaysen GA, et al. HDL glycoprotein composition and site-specific glycosylation differentiates between clinical groups and affects IL-6 secretion in lipopolysaccharide-stimulated monocytes. Sci Rep. 2017;7:43728.PubMedPubMedCentralCrossRef
152.
Ruhaak LR, Kim K, Stroble C, Taylor SL, Hong Q, Miyamoto S, et al. Protein-specific differential glycosylation of immunoglobulins in serum of ovarian cancer patients. J Proteome Res. 2016;15:1002–10.PubMedPubMedCentralCrossRef
153.
Ruhaak LR, Barkauskas DA, Torres J, Cooke CL, Wu LD, Stroble C, et al. The serum immunoglobulin G glycosylation signature of gastric cancer. EuPA Open Proteom. 2015;6:1–9.PubMedCrossRef
154.
Darebna P, Novak P, Kucera R, Topolcan O, Sanda M, Goldman R, et al. Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring. J Proteomics. 2017;153:44–52.PubMedCrossRef
155.
Li Q, Kailemia MJ, Merleev AA, Xu G, Serie D, Danan LM, et al. Site-specific glycosylation quantitation of 50 serum glycoproteins enhanced by predictive glycopeptidomics for improved disease biomarker discovery. Anal Chem. 2019;91:5433–45.PubMedCrossRef
156.
Ramachandran P, Xu G, Huang HH, Rice R, Zhou B, Lindpaintner K, et al. Serum glycoprotein markers in nonalcoholic steatohepatitis and hepatocellular carcinoma. J Proteome Res. 2022;21:1083–94.PubMedPubMedCentralCrossRef
157.
Wu Z, Serie D, Xu G, Zou J. PB-Net: Automatic peak integration by sequential deep learning for multiple reaction monitoring. J Proteomics. 2020;223:103820.PubMedCrossRef
158.
Pickering C, Zhou B, Xu G, Rice R, Ramachandran P, Huang H, et al. Differential peripheral blood glycoprotein profiles in symptomatic and asymptomatic COVID-19. Viruses. 2022;14:553.PubMedPubMedCentralCrossRef
159.
160.
Chandrasekar D, Guerrier C, Alisson-Silva F, Dhar C, Caval T, Schwarz F, et al. Warning signs from the crypt: aberrant protein glycosylation marks opportunities for early colorectal cancer detection. Clin Transl Gastroenterol. 2023;14:e00592.PubMedPubMedCentralCrossRef
161.
Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res. 2008;7:1693–703.PubMedPubMedCentralCrossRef
162.
Pan Y, Zhang L, Zhang R, Han J, Qin W, Gu Y, et al. Screening and diagnosis of colorectal cancer and advanced adenoma by Bionic Glycome method and machine learning. Am J Cancer Res. 2021;11:3002–20.PubMedPubMedCentral
163.
Gu Y, Duan B, Sha J, Zhang R, Fan J, Xu X, et al. Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer. Int J Cancer. 2023;152:536–47.PubMedCrossRef
164.
Takei D, Harada K, Nouso K, Miyahara K, Dohi C, Matsushita H, et al. Clinical utility of a serum glycome analysis in patients with colorectal cancer. J Gastroenterol Hepatol. 2022;37:727–33.PubMedCrossRef
165.
Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res. 2011;17:7035–46.PubMedCrossRef
166.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer Statistics, 2023. CA Cancer J Clin. 2023;73:17–48.PubMedCrossRef
167.
Mulshine JL, D’Amico TA. Issues with implementing a high-quality lung cancer screening program. CA Cancer J Clin. 2014;64:352–63.PubMedCrossRef
168.
Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, et al. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res. 2010;9:6440–9.PubMedPubMedCentralCrossRef
169.
Heo S-H, Lee S-J, Ryoo H-M, Park J-Y, Cho J-Y. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics. 2007;7:4292–302.PubMedCrossRef
170.
Arnold JN, Saldova R, Galligan MC, Murphy TB, Mimura-Kimura Y, Telford JE, et al. Novel glycan biomarkers for the detection of lung cancer. J Proteome Res. 2011;10:1755–64.PubMedCrossRef
171.
Vasseur JA, Goetz JA, Alley WR, Novotny MV. Smoking and lung cancer-induced changes in N-glycosylation of blood serum proteins. Glycobiology. 2012;22:1684–708.PubMedPubMedCentralCrossRef
172.
Fang K, Long Q, Liao Z, Zhang C, Jiang Z. Glycoproteomics revealed novel N-glycosylation biomarkers for early diagnosis of lung adenocarcinoma cancers. Clin Proteomics. 2022;19:43.PubMedPubMedCentralCrossRef
173.
Ahn J-M, Sung H-J, Yoon Y-H, Kim B-G, Yang WS, Lee C, et al. Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol Cell Proteomics. 2014;13:30–48.PubMedCrossRef
174.
Mitchell A, Pickering C, Xu G, Rice R, Castellanos A, Bhadra R, et al. Glycoproteomics as a powerful liquid biopsy-based screening tool for non-small cell lung cancer. J Clin Oncol. 2022;40:e21148–e21148.CrossRef
175.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65:87–108.PubMedCrossRef
176.
177.
178.
Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12:28.PubMedPubMedCentralCrossRef
179.
Ankenbauer KE, Rao TC, Mattheyses AL, Bellis SL. Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics. J Biol Chem. 2023;299:105217.PubMedPubMedCentralCrossRef
180.
Dorsett KA, Jones RB, Ankenbauer KE, Hjelmeland AB, Bellis SL. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells. J Ovarian Res. 2019;12:93.PubMedPubMedCentralCrossRef
181.
Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, et al. The tumor-associated glycosyltransferase ST6GaL-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res. 2016;76:3978–88.PubMedPubMedCentralCrossRef
182.
O’Flaherty R, Muniyappa M, Walsh I, Stöckmann H, Hilliard M, Hutson R, et al. A robust and versatile automated glycoanalytical technology for serum antibodies and acute phase proteins: ovarian cancer case study. Mol Cell Proteomics. 2019;18:2191–206.PubMedPubMedCentralCrossRef
183.
Pan J, Hu Y, Sun S, Chen L, Schnaubelt M, Clark D, et al. Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer. Nat Commun. 2020;11:6139.PubMedPubMedCentralCrossRef
184.
Hu Y, Pan J, Shah P, Ao M, Thomas SN, Liu Y, et al. Integrated proteomic and glycoproteomic characterization of human high-grade serous ovarian carcinoma. Cell Rep. 2020;33:108276.PubMedPubMedCentralCrossRef
185.
Serie D, Moser K, Pickering C, Aiyetan P, Xu G, Rice R, et al. Liquid-biopsy-derived glycoproteomic profiling as a novel means for noninvasive diagnosis of ovarian cancer. J Clin Oncol. 2022;40:e17604–e17604.CrossRef
186.
Lindpaintner K, Pickering C, Mitchell A, Xu G, Cong X, Serie D. Abstract 5314: A peripheral blood-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer. Cancer Res. 2023;83:5314–5314.CrossRef
187.
Lindpaintner K, Srinivasan A, Mitchell A, Dixit A, Xu G, Cong X, et al. 158 A novel, highly accurate liquid biopsy-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2022. p. A171–A171.
188.
Lindpaintner K, Cheng M, Prendergast J, Normington K, Wong M, Xu G, et al. 30 Blood-based glycoprotein signatures in advanced non-small-cell lung carcinoma (NSCLC) receiving first-line immune checkpoint blockade. J Immunother Cancer. 2021;9:A35–A35.CrossRef
189.
Wang Y-N, Lee H-H, Hsu JL, Yu D, Hung M-C. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci. 2020;27:77.PubMedPubMedCentralCrossRef
190.
Lee H-H, Wang Y-N, Xia W, Chen C-H, Rau K-M, Ye L, et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell. 2019;36:168–78.PubMedPubMedCentralCrossRef
191.
Li C-W, Lim S-O, Xia W, Lee H-H, Chan L-C, Kuo C-W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.PubMedPubMedCentralCrossRef
192.
Li C-W, Lim S-O, Chung EM, Kim Y-S, Park AH, Yao J, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33:187–201.PubMedPubMedCentralCrossRef
Metadata
Title
Decoding the glycoproteome: a new frontier for biomarker discovery in cancer
Authors
Kai He
Maryam Baniasad
Hyunwoo Kwon
Tomislav Caval
Gege Xu
Carlito Lebrilla
Daniel W. Hommes
Carolyn Bertozzi
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Biomarkers
Published in
Journal of Hematology & Oncology / Issue 1/2024
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-024-01532-x

Other articles of this Issue 1/2024

Journal of Hematology & Oncology 1/2024 Go to the issue

Correspondence

Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma

Review

Metabolic reprogramming in the tumor microenvironment of liver cancer

Correspondence

A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia

Review

Targeting inflammation as cancer therapy

Research

Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma

Correspondence

Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits